Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma.
10.3346/jkms.2013.28.2.213
- Author:
Sun Hyun BAE
1
;
Mi Sook KIM
;
Chul Koo CHO
;
Kum Bae KIM
;
Dong Han LEE
;
Chul Ju HAN
;
Su Cheol PARK
;
Young Han KIM
Author Information
1. Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea. mskim@kcch.re.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Carcinoma;
Hepatocellular;
Neoplasm Staging;
Radiotherapy;
Stereotactic Techniques
- MeSH:
Adult;
Aged;
Carcinoma, Hepatocellular/mortality/*radiotherapy;
Feasibility Studies;
Female;
Follow-Up Studies;
Humans;
Liver Failure/etiology;
Liver Neoplasms/mortality/*radiotherapy;
Male;
Middle Aged;
Myelitis/etiology;
Neoplasm Staging;
Prognosis;
Radiation Dosage;
Retrospective Studies;
Severity of Illness Index;
Stereotaxic Techniques;
Survival Rate
- From:Journal of Korean Medical Science
2013;28(2):213-219
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to assess the feasibility and efficacy of stereotactic ablative radiotherapy (SABR) for liver tumor in patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). We retrospectively reviewed the medical records of 35 patients between 2003 and 2011. Vascular invasion was diagnosed in 32 patients, extrahepatic metastases in 11 and both in 8. Thirty-two patients were categorized under Child-Pugh (CP) class A and 3 patients with CP class B. The median SABR dose was 45 Gy (range, 30-60 Gy) in 3-5 fractions. The median survival time was 14 months. The 1- and 3-yr overall survival (OS) rate was 52% and 21%, respectively. On univariate analysis, CP class A and biologically equivalent dose > or = 80 Gy10 were significant determinants of better OS. Severe toxicity above grade 3, requiring prompt therapeutic intervention, was observed in 5 patients. In conclusion, SABR for BCLC-C stage HCC showed 1-yr OS rate of 52% but treatment related toxicity was moderate. We suggest that patients with CP class A are the best candidate and at least SABR dose of 80 Gy10 is required for BCLC-C stage.
